Theraputic Update 2026

Pharmacogenomics and Updates in Diabetes Management

1. Describe the current framework, recommendations, and evidence to apply patient specific pharmacogenomic information to individualized treatment decisions.

2. Evaluate various drug interactions and patient specific pharmacogenomic drug interaction considerations.

3. Discuss guideline updates in the management of diabetes mellitus, including cardiovascular and renal considerations and their impact on pharmacotherapy selection .

4. Identify how continuous glucose monitors can be utilized to optimize pharmacotherapy regimens for patients with diabetes.

5. Apply the updates discussed for vaccinations, hormonal and osteoporosis therapies, and diabetes management through a series of interactive patient cases and discussions .

6. Define the appropriate workup for several interactive cases of acute abdominal pain.

7. Illustrate the pitfalls in making a diagnosis.

Peptic Ulcer Disease and Helicobacter Highlights:

1. Identify the importance of risk factors in the development of UGI bleeding.

2. Select appropriate candidates for long term PPI therapy.

3. Review noninvasive ways of making a H pylori diagnosis.

4. Manage antibiotic therapy for Helicobacter 2024.

Clinical Dilemmas in GI Bleeding:

1. Describe the limitations of colonoscopy.

2. Recognize the importance of “Alarm Symptoms”.

3. Describe advanced endoscopic techniques that are used to evaluate

GI bleeding.

1. Recognize the safe use of anti platelet and anticoagulation medications post GI bleedng

1. Discuss why individuals with profound autism have reduced access to inpatient psychiatric hospitalization.

2. Define polypharmacy.

3. Identify three reasons for polypharmacy in people with profound autism.

4. Apply deprescribing strategies to a clinical case example.

5. Define diagnostic overshadowing and evaluate factors that may contribute to it using a clinical case example.

6. Identify three common psychotropic side effects and assess how they contribute to aggression and self-injurious behaviors in people with intellectual disabilities.

7. Distinguish between affective and mood lability and describe how those differences influence treatment planning.

8. Describe the diagnostic and treatment differences of catatonia in people with and without an intellectual disability.

9. Formulate a treatment plan for an individual with profound autism and excited catatonia.

• Describe the basic pharmacology behind monoclonal antibodies.

• Discuss how monoclonal antibodies are made.

• Discuss the nomenclature behind naming monoclonal antibodies.

• List examples of monoclonal antibodies and the conditions they treat.
  

• Outline in STEPS format (safety, tolerability, efficacy, price, simplicity) several monoclonal antibodies (i.e., Certolizumab, denosumab, new cholesterol medications.)
  Discuss the side effects of selected monoclonal antibodies.

• Discuss risk factors associated with these new technologies.

• List any general patient education.